News Center
Bora Wins Prestigious CDMO Leadership Awards TAIPEI, TAIWAN, March 20, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the
43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been invited to participate in the prestigious J.P. Morgan Healthcare Conference
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer TAIPEI, TAIWAN –
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan Taipei, Taiwan (January 6, 2025) – Bora
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: “Deal of the Year” Award and “Best Cross-Border M&A”
Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business TAIPEI, TAIWAN, October 3, 2024 – Bora
Taipei, Taiwan – September 4, 2024 – Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the biosimilar-focused biopharmaceutical company
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that
We are attending 2024 CPHI Milan and are excited to discuss how our new capabilities and our comprehensive global service
TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global leader